Zacks Investment Research
07 Aug 2026, 08:46 UTC · 6w ago
Verdict
Source says Buy. We score BCAL +0.80 across three claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
NexPoint Residential Trust (NXRT) has seen its current year earnings consensus estimate increase by 9.3% over the last 60 days.
More positive than 62% of claims this week
Supernus Pharmaceuticals (SUPN) has seen its current year earnings consensus estimate increase by 7.6% over the last 60 days.
Continue reading
5 related stories
More positive than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 55% of claims this week
California BanCorp (BCAL) has seen its next year earnings consensus estimate increase by 5% over the last 60 days.
So whatWhile positive, the impact is slightly lower as the revision pertains to next year rather than the current year.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Company has a Zacks Rank #1 and positive earnings estimate revisions.
More positive than 84% of ticker scores this week
Company has a Zacks Rank #1 and positive earnings estimate revisions.
More positive than 84% of ticker scores this week
Company has a Zacks Rank #1 and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+1.3%
Price agrees with the score
$21.64 vs $21.37 close before publication (Aug 6) · not market-adjusted
BCAL chart →